title: Investigation of the efficacy and tolerability of Dr Michaels® (also branded as Eczitinex® and Itchinex Eczitinex®) topical products in the treatment of atopic dermatitis in children.
abstract: Atopic eczema is a chronic relapsing inflammatory skin disorder, characterized clinically by intensely pruritic eczematous skin lesions and a defective epidermal barrier. It affects more than 15% of children and up to 10%of adults, which makes the disease a social health problem still without a challenging treatment. The aim of this study was to evaluate the efficacy and tolerability of Dr Michaels® (Eczitinex®) topical product family in the treatment of atopic dermatitis in children. We studied a group of 30 patients (17 female, 13 male), aged 5 to 13 (mean age: 9), affected by atopic dermatitis since they were newborn. All patients had been unsuccessfully treated with conventional anti-inflammatory therapies and ceased treatment 2 weeks before commencing research. The patients were treated with Dr Michaels® (Eczitinex® and Itchinex®) product family including a moisturising bar, topical ointment and PSC 900 oral herbal formulation. The treatment was evaluated clinically and photographically at 0, 1, 2, 4, 6, 8, 10, 12, and 14 weeks. Twenty-eight patients showed a significant improvement of cutaneous rashes and pruritus on the first week of treatment, with a complete remission at 10-12 weeks. Only two patients, brother and sister respectively, showed a slow response to treatment and reported an increasing itching. Following 14 weeks of treatment with the Dr Michaels® (Eczitinex® and Itchinex®) product family, patients demonstrated complete resolution of their AD. All patients showed a marked improvement in their condition within 3 days of treatment with most of the lesions and symptoms totally resolved within 10 to 12 weeks of treatment with Dr Michaels® (Eczitinex® and Itchinex®) family of products. This clinical report highlights that the Dr Michaels® (Eczitinex® and Itchinex®) product family is a safe and effective treatment option for AD.
authors: Department of Dermatology and Cutaneous Surgery, Department of Psychiatry and Behavioral Sciences, Institute for Bioethics and Health Policy, University of Miami, Miller School of Medicine, Miami, FL, USA; Centro Studi per la Ricerca Multidisciplinare e Rigenerativa, Università Degli Studi "G. Marconi", Rome, Italy.
authors: K
authors: K
authors: França
authors: 2nd Medical Faculty, Charles University, Bulovka Hospital, Institute of Clinical and Experimental Medicine, Prague, Czech Republic.
authors: J
authors: J
authors: Hercogovấ
authors: Department of Nuclear Physics, Sub-nuclear and Radiation, G. Marconi University, Rome, Italy.
authors: M
authors: M
authors: Fioranelli
authors: Dermatological Department University of Pisa, Pisa, Italy.
authors: S
authors: S
authors: Gianfaldoni
authors: Onkoderma-Policlinic for dermatology and dermatologic surgery, Sofia, Bulgaria; 7 Department of Dermatology and Venereology, Medical University of Plovdiv, Medical faculty, Plovdiv, Bulgaria.
authors: A A
authors: AA
authors: Chokoeva
authors: Medical Institute of Ministry of Interior (MVR), Department of Dermatology, Venereology and Dermatologic Surgery, Sofia, Bulgaria.
authors: G
authors: G
authors: Tchernev
authors: Department of Dermatology and Allergology, Academic Teaching Hospital Dresden-Friedrichstadt, Dresden, Germany.
authors: U
authors: U
authors: Wollina
authors: Psoriasis and Skin Clinic, Melbourne, Australia.
authors: M
authors: M
authors: Tirant
authors: Psoriasis and Skin Clinic, Melbourne, Australia.
authors: P
authors: P
authors: Bayer
authors: Psoriasis and Skin Clinic, Melbourne, Australia.
authors: M
authors: M
authors: Coburn
authors: Psoriasis and Skin Clinic, Melbourne, Australia.
authors: P
authors: P
authors: Anderson
authors: Psoriasis and Skin Clinic, Melbourne, Australia.
authors: B
authors: B
authors: Donnelly
authors: Psoriasis and Skin Clinic, Melbourne, Australia.
authors: T
authors: T
authors: Kennedy
authors: Psoriasis and Skin Clinic, Melbourne, Australia.
authors: J
authors: J
authors: Gaibor
authors: Psoriasis and Skin Clinic, Melbourne, Australia.
authors: M
authors: M
authors: Arora
authors: Psoriasis and Skin Clinic, Melbourne, Australia.
authors: L
authors: L
authors: Clews
authors: PRO SANUM Ltd, Sanatorium of Prof. Novotný, Štěpánská Prague 1, Czech Republic.
authors: F
authors: F
authors: Novotny
authors: University B.I.S. Group of Institutions, Punjab Technical University, Punjab, India.
authors: M G
authors: MG
authors: Roccia
authors: Department Medicinal Information and Non-interventional studies, Bulgarian Drug Agency, Sofia, Bulgaria.
authors: G K
authors: GK
authors: Maximov
authors: Chair of Dermatology, University of Rome G. Marconi Rome, Italy.
authors: T
authors: T
authors: Lotti
mesh_terms: D000279:Administration, Cutaneous; D000293:Adolescent; D002648:Child; D002675:Child, Preschool; D003876:Dermatitis, Atopic / Q000188:drug therapy / Q000628:therapy*; D005260:Female; D006801:Humans; D008297:Male; D009824:Ointments / Q000008:administration & dosage* / Q000009:adverse effects / Q000627:therapeutic use*; D008517:Phytotherapy / Q000009:adverse effects; D012867:Skin / Q000187:drug effects; D016896:Treatment Outcome
chemical_list: D009824:Ointments